Why Pharmaceutical Companies Outsource Clinical Trials to CROs
Running a Phase III clinical trial in-house is possible. However, it requires significant infrastructure, global site networks, regulatory expertise, data systems, and experienced teams. Even large pharmaceutical companies do not run all trials internally. For midsize pharma, biotech, and emerging companies, building this infrastructure for every program is neither practical nor cost-effective. This is exactly why outsourcing clinical trials to CROs has become the standard operating model across the pharmaceutical industry. The capabilities required to run modern, multinational clinical trials are [...]
